Logo Image
Viewing
Opinion|Videos|February 7, 2025

Outcomes with Faricimab and Choosing Between the New Therapies

Panelists discuss how faricimab’s dual inhibition of Ang-2 provides additional benefits in vascular stability and inflammation reduction beyond VEGF-A suppression alone, potentially leading to improved durability and treatment outcomes in selected patients.

Episodes in this series

Video content above is prompted by the following:

  • In clinical trials, faricimab showed noninferior vision outcomes compared to aflibercept 2 mg. What added benefit do you see by targeting Ang-2?

Related Content

Latest CME

Precision Vision: Integrating Mechanistic Insight and Clinical Strategy in ADC-Associated Ocular Toxicity
Video

Precision Vision: Integrating Mechanistic Insight and Clinical Strategy in ADC-Associated Ocular Toxicity

Neel Pasricha, MD; Asim V. Farooq, MD; Susana Campos, MD, MPH

View more
Treatment Optimization in the Evolving Anti-VEGF Era
Video

Treatment Optimization in the Evolving Anti-VEGF Era

Carl Danzig, MD, FASRS; Sruthi Arepalli, MD; Priya Vakharia, MD, FASRS

View more
When Mites Meet Their Match: Empowering Patients With Targeted Treatment for 𝘋𝘦𝘮𝘰𝘥𝘦𝘹 Blepharitis
Video

When Mites Meet Their Match: Empowering Patients With Targeted Treatment for 𝘋𝘦𝘮𝘰𝘥𝘦𝘹 Blepharitis

Mile Brujic, OD, FAAO; Pierce Kenworthy, OD, FAAO; Blair Lonsberry, MS, OD, MEd, FAAO

View more
(COPE) The Truth About Presbyopia Drops: Evidence-Based Cases and Myth-Busting Insights
Video

(COPE) The Truth About Presbyopia Drops: Evidence-Based Cases and Myth-Busting Insights

Damon Dierker, OD FAAO; Maria Pribis, OD

View more
(CME Track) Emerging Therapeutic Advancements in Dry Eye Disease Management
Video

(CME Track) Emerging Therapeutic Advancements in Dry Eye Disease Management

Rahul Tonk, MD; Jade Coats, OD, FAAO; Aaleya Koreishi, MD; Zeba Syed, MD

View more